Lunai Bioworks Statistics
Total Valuation
Lunai Bioworks has a market cap or net worth of $9.08 million. The enterprise value is $7.33 million.
Important Dates
The last earnings date was Friday, May 15, 2026, after market close.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lunai Bioworks has 36.27 million shares outstanding. The number of shares has increased by 39.92% in one year.
| Current Share Class | 36.27M |
| Shares Outstanding | 36.27M |
| Shares Change (YoY) | +39.92% |
| Shares Change (QoQ) | +6.44% |
| Owned by Insiders (%) | 19.66% |
| Owned by Institutions (%) | 2.73% |
| Float | 26.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 433.34 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 350.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.61 |
Financial Efficiency
Return on equity (ROE) is -325.46% and return on invested capital (ROIC) is -14.02%.
| Return on Equity (ROE) | -325.46% |
| Return on Assets (ROA) | -9.65% |
| Return on Invested Capital (ROIC) | -14.02% |
| Return on Capital Employed (ROCE) | 104.51% |
| Weighted Average Cost of Capital (WACC) | 9.99% |
| Revenue Per Employee | $722 |
| Profits Per Employee | -$4.42M |
| Employee Count | 29 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.23% in the last 52 weeks. The beta is 0.33, so Lunai Bioworks's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -92.23% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 35.20 |
| Average Volume (20 Days) | 8,427,415 |
Short Selling Information
The latest short interest is 1.65 million, so 4.56% of the outstanding shares have been sold short.
| Short Interest | 1.65M |
| Short Previous Month | 779,601 |
| Short % of Shares Out | 4.56% |
| Short % of Float | 6.17% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, Lunai Bioworks had revenue of $20,942 and -$128.28 million in losses. Loss per share was -$5.78.
| Revenue | 20,942 |
| Gross Profit | 20,942 |
| Operating Income | -9.85M |
| Pretax Income | -128.28M |
| Net Income | -128.28M |
| EBITDA | -9.74M |
| EBIT | -9.85M |
| Loss Per Share | -$5.78 |
Full Income StatementBalance Sheet
The company has $3.16 million in cash and $1.41 million in debt, with a net cash position of $1.74 million or $0.05 per share.
| Cash & Cash Equivalents | 3.16M |
| Total Debt | 1.41M |
| Net Cash | 1.74M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | -9.55M |
| Book Value Per Share | -0.27 |
| Working Capital | -15.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.26 million and capital expenditures -$1,238, giving a free cash flow of -$5.26 million.
| Operating Cash Flow | -5.26M |
| Capital Expenditures | -1,238 |
| Depreciation & Amortization | 104,965 |
| Net Borrowing | 3.93M |
| Free Cash Flow | -5.26M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -47,019.40% |
| Pretax Margin | -612,568.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
